Oncology Venture

OMX: OV.ST

SEK237.5m market cap

SEK3.37 last close

Oncology Venture is a biopharmaceutical company with a patent-protected mRNA-based drug response predictor platform that identifies patients highly likely to respond to treatment. The company is entering Phase II with six in-licensed drugs.

Investment summary

Oncology Venture holds the worldwide drug development rights to the drug response predictor (DRP), a microarray technology that examines the expression of a panel of genes to identify potential responders to different cancer therapies. The company’s goal is to then develop is portfolio of drugs that are active within populations that the DRP can identify. To date, the company has in-licensed six drugs and has an option to a seventh drug and is in the early stages of validating the platform in prospective trials in the clinic.

Y/E Dec
Revenue (DKKm)
EBITDA (DKKm)
PBT (DKKm)
EPS (ore)
P/E (x)
P/CF (x)
2017A 5.1 (23.8) (31.0) (127.00) N/A N/A
2018A 2.1 (32.3) (22.5) (44.00) N/A N/A
2019E 3.6 (210.6) (211.1) (264.34) N/A N/A
2020E 3.6 (96.9) (96.0) (124.58) N/A N/A
Last updated on 25/07/2019
Industry outlook

Oncology Venture and the DRP system have the potential to identify the value in drug assets that have otherwise been discontinued by identifying patient populations where these drugs are active. This allows the company to in-license these assets at low cost, which the company may then out-license after clinical validation.

Last updated on 25/07/2019
Sector
Healthcare
Share price graph
Balance sheet
Forecast net debt (DKKm) 128.5
Forecast gearing ratio (%) 372
Price performance
%
1m
3m
12m
Actual 8.7 (24.4) (56.0)
Relative* 7.6 (23.4) (57.9)
52-week high/low SEK12.7/SEK3.0
*% relative to local index
Key management
Peter Buhl Jensen CEO
Ulla Hald Buhl Chief Operating Officer